Real-World Outcomes of Atezolizumab With Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications

• DOI: 10.20944/preprints202407.0186.v1
• Publication Date: 2024-07-02T08:18:49Z
• Authors: Cha Len Lee; Mark Freeman; Kelly W. Burak; Gordon T. Moffat; Conor O'Donnell; Philip Q. Ding; Hanna Lyubetska; Brandon M. Meyers; Vallerie Gordon; Ekaterina Kosyach...; Roxana Bucur; Winson Y. Cheung; Jennifer J. Knox; Vincent C Tam
• Keywords: Esophagogastroduodenoscopy; Atezolizumab

The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. necessity mandatory EGD all patients remains unclear. We retrospectively analyzed 112 HCC treated A+B at five Canadian cancer centers July 1, 2020, August 31, 2022. was the first-line therapy 90% patients, median overall survival 20.3 and progression-free 9.6 months. There no difference between those without. Before A+B, 71%(79) underwent months, revealing varices in 41%(32) requiring intervention 19%(15). rate 15%(17), GI-specific occurring 83%(5) group 17%(1) non-EGD (p=0.24). Non-GI observed 10%(11) patients. Outcomes Canada were comparable IMbrave150. Our study showed twice detection compared IMbrave150, reflecting real-world high-risk populations. increased GI without pre-treatment EGD, supporting a selective approach.